These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 30827763)

  • 41. Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study.
    Vaz-Luis I; Seah D; Olson EM; Wagle N; Metzger-Filho O; Sohl J; Litsas G; Burstein HJ; Krop IE; Winer EP; Lin NU
    Clin Breast Cancer; 2013 Aug; 13(4):254-63. PubMed ID: 23829891
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.
    Trédan O; Ménétrier-Caux C; Ray-Coquard I; Garin G; Cropet C; Verronèse E; Bachelot T; Rebattu P; Heudel PE; Cassier P; Chabaud S; Croughs T; Dupont P; Cadore AC; Clapisson G; Delgado A; Bardin-dit-Courageot C; Rigal C; N'Kodia A; Gilles-Afchain L; Morre M; Pérol D; Blay JY; Caux C
    Ann Oncol; 2015 Jul; 26(7):1353-62. PubMed ID: 25851629
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Loss of Lymph Node Metastases After Neoadjuvant Chemotherapy in Patients With Cytology-proven Axillary Node-positive Primary Breast Cancer.
    Namura M; Tsunoda H; Kobayashi D; Enokido K; Yoshida A; Watanabe T; Suzuki K; Nakamura S; Yamauchi H; Hayashi N
    Clin Breast Cancer; 2019 Aug; 19(4):278-285. PubMed ID: 30975473
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Do clinical features and survival of single hormone receptor positive breast cancers differ from double hormone receptor positive breast cancers?
    Ng CH; Pathy NB; Taib NA; Ho GF; Mun KS; Rhodes A; Looi LM; Yip CH
    Asian Pac J Cancer Prev; 2014; 15(18):7959-64. PubMed ID: 25292095
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
    Le D; Speers C; Thompson L; Gondara L; Nichol A; Lohrisch C
    Cancer; 2020 Mar; 126(5):971-977. PubMed ID: 31750938
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival.
    Tarhan MO; Demir L; Somali I; Yigit S; Erten C; Alacacioglu A; Ellidokuz H; Seseogullari O; Kucukzeybek Y; Can A; Dirican A; Bayoglu V; Akyol M
    Clin Exp Metastasis; 2013 Feb; 30(2):201-13. PubMed ID: 22915160
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
    Ibrahim T; Farolfi A; Scarpi E; Mercatali L; Medri L; Ricci M; Nanni O; Serra L; Amadori D
    Oncology; 2013; 84(3):150-7. PubMed ID: 23257904
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
    Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
    Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
    Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
    Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology.
    Blohmer M; Zhu L; Atkinson JM; Beriwal S; Rodríguez-López JL; Rosenzweig M; Brufsky AM; Tseng G; Lucas PC; Lee AV; Oesterreich S; Jankowitz RC
    Breast Cancer Res; 2020 Jun; 22(1):70. PubMed ID: 32586354
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.
    Serpico D; Porcu L; Tessari A; Gevorgyan A; Bregni G; Galli G; de Braud F; Torri V; Di Cosimo S
    Clin Transl Oncol; 2015 Jul; 17(7):530-8. PubMed ID: 25604128
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
    Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
    Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
    Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes.
    Murphy BL; Day CN; Hoskin TL; Habermann EB; Boughey JC
    Ann Surg Oncol; 2018 Aug; 25(8):2241-2248. PubMed ID: 29786125
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
    Park HS; Sohn J; Kim SI; Park S; Park HS; Gho SG; Chung HC; Paik S; Kim GM
    Breast Cancer Res Treat; 2017 Jun; 163(2):255-262. PubMed ID: 28243895
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.
    Blancas I; Fontanillas M; Conde V; Lao J; Martínez E; Sotelo MJ; Jaen A; Bayo JL; Carabantes F; Illarramendi JJ; Gordon MM; Cruz J; García-Palomo A; Mendiola C; Pérez-Ruiz E; Bofill JS; Baena-Cañada JM; Jáñez NM; Esquerdo G; Ruiz-Borrego M
    Clin Transl Oncol; 2018 Jul; 20(7):862-869. PubMed ID: 29178019
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 Years.
    Chen X; Fan Y; Xu B
    Clin Breast Cancer; 2018 Dec; 18(6):e1353-e1360. PubMed ID: 30201586
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.
    Kawaguchi H; Masuda N; Nakayama T; Aogi K; Anan K; Ito Y; Ohtani S; Sato N; Saji S; Takano T; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita H; Yamashita T; Yamamoto Y; Yotsumoto D; Toi M; Ohno S
    Breast Cancer; 2020 May; 27(3):389-398. PubMed ID: 31811519
    [TBL] [Abstract][Full Text] [Related]  

  • 60. B
    Stueber TN; Wischnewsky M; Leinert E; Diessner J; Bartmann C; Stein RG; Woeckel A
    Clin Breast Cancer; 2019 Oct; 19(5):333-339. PubMed ID: 31281053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.